Truist raised its price target on Progyny to $33 from $30 while maintaining a Buy rating following meetings with the company's management team. The firm cited Progyny's differentiated fertility benefits model, superior clinical outcomes, and comprehensive member services as key strengths. Earlier, BofA increased its target to $31 from $29, pointing to favorable fertility prescription trends and rising Google search activity that suggest utilization is tracking ahead of expectations. Progyny specializes in fertility, family-building, and women's health benefits management, with a projected five-year EPS growth rate of 40.83%.
Progyny IncTruist raised price target to $33 and BofA to $31, both citing positive fundamentals.